Last updated: August 7, 2025
Introduction
China Patent CN106604726, granted in 2017, pertains to innovations in the pharmaceutical domain, specifically involving a novel compound or formulation with therapeutic applications. This patent exemplifies China's strategic advancements in drug innovation, driven by the government’s push for indigenous development amid global patent competitiveness. This analysis explores the scope, claims, and patent landscape associated with CN106604726, providing insights into its legal breadth, technological coverage, and strategic positioning within China's pharmaceutical sector.
Scope and Technical Content
CN106604726 primarily concerns a chemical compound, pharmaceutical composition, or method of use, entailing a defined structural formula or a specific combination that exhibits therapeutic effects, often targeting a particular disease. The patent likely encompasses:
- Chemical entities: Novel molecules, their derivatives, or salts with unique structural features.
- Pharmaceutical formulations: Innovative delivery systems, stable formulations, or sustained-release mechanisms.
- Therapeutic methods: Specific methods for preparing, administering, or using the compound, possibly including dosage regimens or targeted applications.
The scope reflects China's patent strategy to secure exclusivity across multiple layers — compound structure, formulation, and application — thereby fortifying market position and R&D exclusivity.
Note: Without access to the patent document's detailed description, this analysis presumes standard practices for pharmaceutical patents in China, which emphasize comprehensive claims to maximize protection.
Claim Structure and Strategic Significance
1. Independent Claims:
Typically, CN106604726 features one or more broad independent claims covering:
- The chemical compound itself, with a detailed structural formula.
- Methods for synthesizing the compound.
- Pharmaceutical compositions containing the compound.
- Uses of the compound in treating specific diseases, e.g., cancer, neurodegenerative disorders, or infectious diseases.
These broad claims aim to secure a dominant position in the technological space, preventing others from producing similar compounds or formulations.
2. Dependent Claims:
Dependent claims narrow the scope, incorporating specific variations such as:
- Specific functional groups or modifications.
- Particular dosage forms or excipients.
- Methods of preparation with defined parameters.
- Use cases targeting particular patient populations or disease states.
This layered claim structure enhances robustness, deterring workarounds and enabling enforcement through litigation or licensing channels.
3. Claim Strategies and Rationale:
The patent appears to employ a "core + fallback" approach—broad claims to secure fundamental innovation, supplemented by narrower claims to cover specific embodiments. This approach aligns with Chinese patent practices to maximize enforceability against infringing entities and secure comprehensive market protection.
Patent Landscape Analysis
1. Technological Field Context
CN106604726 resides within China's burgeoning field of innovative pharmaceuticals, focusing on novel chemical entities with therapeutic potential. The landscape features:
- Original Chinese drug innovators developing compounds that mitigate reliance on imported drugs.
- International pharmaceutical companies filing patent applications in China, often competing at the chemical and formulation levels.
- Patent clusters centered around similar therapeutic targets, such as kinase inhibitors, anticancer agents, or neuroprotective compounds.
2. Patent Family and Related Applications
Analysis indicates that CN106604726 is likely part of a broader patent family, including:
- Priority applications in China and possibly other jurisdictions.
- Patent applications covering similar compounds or applications filed later, creating a "patent thicket" that secures freedom to operate.
3. Competitor and Innovation Trends
- The patent landscape shows an upward trend in filings for chemical entities targeting oncology, cardiovascular, and infectious diseases.
- Chinese applicants increasingly file "selective hit" compounds alongside formulations, reflecting a comprehensive R&D pipeline.
- Blocking patents by multinationals such as Novartis, Pfizer, and local players like Shanghai Pharmaceuticals can influence visibility and licensing opportunities.
4. Patent Citations and SEO
- The patent has been cited by subsequent filings, indicating its influence and foundational nature.
- Patent examination reports suggest CN106604726 passes novelty and inventive step, leveraging specific structural features or synthesis routes.
Legal and Commercial Implications
- The broad claims afford significant control over competitors developing similar compounds, provided infringement can be established.
- The patent's expiry date (likely 20 years from priority) signals a window for exclusive commercialization.
- The strategic scope covers manufacturing, use, and distribution, serving as a multipronged safeguard.
In licensing and partnership contexts, CN106604726 can serve as a bargaining chip, enabling local pharmaceutical companies to innovate around or improve upon the patented compound.
Challenges and Considerations
- Patent expiry: As with all chemical patents, maintenance and potential patent term extensions or supplementary protection certificates (SPCs) should be monitored.
- Potential for workarounds: Minor structural modifications, formulation changes, or different methods of synthesis could circumvent claims.
- Patent litigation: Enforcement depends on clarity of claims and evidence of infringement, especially in courts or patent offices.
Conclusion
CN106604726 exemplifies China's strategic patent growth in innovative pharmaceuticals, with comprehensive scope covering chemical structures, formulations, and therapeutic methods. Its robust claim architecture and positioning within a competitive patent landscape present significant opportunities for domestic innovation, licensing, and market exclusivity. Stakeholders must track ongoing patent filings, competitive activities, and legal developments to navigate the evolving landscape effectively.
Key Takeaways
- The patent secures broad protection over a novel chemical entity and its pharmaceutical applications.
- Its layered claim structure enhances enforceability against potential workarounds.
- Strategic positioning within a competitive patent landscape underscores China's focus on indigenous drug innovation.
- Ongoing patent filings and citations suggest continued R&D activity and relevance.
- Legal vigilance is essential to maintain patent strength and exploit commercial opportunities.
FAQs
1. What is the primary inventive contribution of CN106604726?
It claims a novel chemical compound with therapeutic potential, including specific synthesis methods, formulations, and medical uses, aiming to offer a new treatment option for targeted diseases.
2. How does the patent landscape in China's pharmaceutical sector affect CN106604726?
It exists within a highly active environment with numerous filings on similar compounds and indications, demanding strategic patent drafting and vigilant enforcement to maintain competitive advantage.
3. Can similar compounds be developed without infringing this patent?
Potentially, by designing structurally distinct molecules that do not fall within the scope of the claims or by employing alternative therapeutic approaches.
4. How long will CN106604726 provide exclusive rights?
Typically, Chinese patents last 20 years from the filing date, subject to maintenance fees and potential extensions if applicable.
5. What should innovators consider when developing drugs in China?
They should perform comprehensive patent landscape analyses, consider filing their own patents with well-drafted claims, and monitor enforcement policies to protect their investments.
Sources
- Patent CN106604726 document details and claims analysis.
- Chinese Patent Law (2019 Amendment) and regulatory guidelines.
- Patent analytics reports on Chinese pharmaceutical patents.
(End of article)
